Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
miRNA1827 agomir
- Development stage
- Preclinical
- Modality
- MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intratumoral
01
Overview
miRNA1827 agomir is a synthetic RNA therapeutic designed to mimic the action of microRNA-1827, restoring or enhancing its biological activity in target cells. As an agomir, it is a chemically modified, stable oligonucleotide that increases the activity of endogenous miR-1827. In non-small cell lung cancer (NSCLC), miRNA1827 agomir was shown to inhibit platinum resistance and promote pyroptosis by targeting methyl-CpG binding domain protein 3 (MBD3). This disrupts MBD3-mediated repression of gasdermin E (GSDME), which is required for pyroptosis, thereby sensitizing tumors to platinum-based chemotherapy. miRNA1827 agomir is used in preclinical models by intratumoral injection and in combination with chemotherapies to overcome chemoresistance[1][3].
- Brand names
- miRNA1827 agomirmiRNA-1827 agomirmiRNA 1827 agomir
- Other names
- miR-1827 agomirmiR1827 agomirmiR 1827 agomir
02
Targets
GSDME (Gasdermin E)MBD3 (Methyl-CpG-binding domain protein 3)
Beyond the preview
Go deeper on miRNA1827 agomir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on miRNA1827 agomir.